ADMT vs SYK vs ABT Stock Comparison

Adm Tronics Unlimited, Stryker and Abbott Laboratories Prices as of Nov 3, 2026 Peers: Industry group
1 more company in this comparison (DXCM) Create a free account to keep reading and compare up to 10 companies.
SYK Stryker Corp
$310.57 +12.7% 1M -13.3% 1Y
Market cap
$130.89B
P/E
36.1x
Revenue (TTM)
$26.30B
Div. yield
–
Medical Devices Healthcare
5 wins
ABT Abbott Laboratories
$109.41 +12.2% 1M -11.7% 1Y
Market cap
$201.46B
P/E
37.1x
Revenue (TTM)
$46.59B
Div. yield
0.02%
Medical Devices Healthcare
5 wins

Head to Head

11 decided of 12

Abbott Laboratories leads on 5 of the 12 questions below (Abbott Laboratories 5, Stryker 5, Adm Tronics Unlimited 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionADMTSYKABTLeader
Larger companyMarket capitalisation $4.73M $130.89B $201.46B ABT
Cheaper on earningsLower P/E, profitable companies only -12.0x 36.1x 37.1x SYK
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 19.5x 19.2x ABT
Faster revenue growthRevenue growth, trailing twelve months -2.2% +7.9% +8.1% ABT
More profitableNet margin, trailing twelve months -12.2% 13.8% 11.6% SYK
Better return on capitalReturn on invested capital -27.1% 10.0% 6.2% SYK
Less leveragedLower net debt / EBITDA -0.9x 1.8x 2.5x ADMT
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.02% –
Better 1-year returnPrice return, last 12 months -33.3% -13.3% -11.7% ABT
Better 5-year returnAnnualised price return, 5 years -11.4%/yr +2.8%/yr -3.3%/yr SYK
Less volatileAnnualised volatility, 1 year 185.7% 31.6% 27.8% ABT
Higher overall scoreMean of the five percentile scores vs peers 29/100 69/100 56/100 SYK

Percentile Scorecard

ADMTSYKABT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisADMTSYKABT
Valuation 50 #115 of 229 67 #77 of 229 66 #78 of 229
Growth 2 #216 of 221 62 #84 of 221 29 #157 of 221
Profitability 46 #113 of 209 89 #23 of 209 85 #33 of 209
Financial Health 17 #200 of 240 48 #125 of 240 36 #153 of 240
Shareholder Returns – 77 #35 of 147 66 #51 of 147
Overall 29 69 56
  • ADMT ranked among 248 companies in Medical Devices and Diagnostics
  • SYK ranked among 248 companies in Medical Devices and Diagnostics
  • ABT ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodADMTSYKABTSPY
1 month +20.0%+12.7%+12.2% -2.0%
3 months +50.0%-7.5%+3.7% -2.2%
6 months -25.0%+5.2%+25.5% +4.2%
Year to date -40.0%-11.6%-12.7% +10.6%
1 year -33.3%-13.3%-11.7% +10.4%
3 years -45.5%+12.4%+14.2% +73.6%
3 years, per year -18.3%+4.0%+4.5% +20.2%
5 years -45.5%+15.0%-15.2% +61.6%
5 years, per year -11.4%+2.8%-3.3% +10.1%
10 years -68.4%+168.5%+185.1% +261.3%
10 years, per year -10.9%+10.4%+11.0% +13.7%

Risk

MeasureADMTSYKABTSPY
Volatility, 1Y 185.7%31.6%27.8% 12.8%
Downside volatility, 1Y 353.6%32.9%27.5% 12.8%
Beta vs S&P 500, 1Y -1.300.18-0.04 1.00
Return / volatility, 1Y -0.18-0.42-0.42 0.81
Max drawdown, 5Y -80.0%-33.1%-41.6% -25.4%
From 52-week high -50.0%-19.8%-16.2% -3.2%
52-week high $0.12$387.46$130.59 $779.14
52-week low $0.03$269.88$82.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleADMTSYKABT
P/E now vs peer median -10.2xmedian 28.1x 32.9xmedian 28.1x 35.1xmedian 28.1x
P/S now vs peer median 1.3xmedian 2.9x 4.5xmedian 2.9x 4.1xmedian 2.9x
EV/EBITDA now vs peer median -16.5xmedian 18.0x 19.6xmedian 18.0x 20.0xmedian 18.0x
P/FCF now vs peer median -25.8xmedian 24.8x 25.9xmedian 24.8x 24.2xmedian 24.8x
P/B now vs peer median 6.7xmedian 2.3x 5.0xmedian 2.3x 3.7xmedian 2.3x
PEG now vs peer median 0.37median 0.95 2.81median 0.95 19.31median 0.95

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsADMTSYKABT
Revenue $3.24M $26.30B $46.59B
Gross profit $1.27M $17.18B $26.37B
Operating income -$288.99K $5.43B $7.35B
Net income -$395.64K $3.62B $5.43B
Free cash flow -$157.02K $4.57B $7.82B
R&D $522.65K $1.68B $3.16B
EPS (diluted) $-0.01 $9.39 $3.11
Cash & equivalents $222.62K $3.27B $5.10B
Total debt $448.85K $14.93B $32.61B
Shares (diluted) 67.59M 386.00M 1.74B
Enterprise value $3.63M $117.08B $171.89B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricADMTSYKABT
P/E -10.2x 32.9x 35.1x
P/FCF -25.8x 25.9x 24.2x
P/Operating cash flow -25.8x 21.7x 19.1x
P/S 1.3x 4.5x 4.1x
P/B 6.7x 5.0x 3.7x
P/Tangible book 6.8x 6.6x 5.5x
EV/EBITDA -16.5x 19.6x 20.0x
EV/EBIT -14.8x 23.9x 29.4x
EV/Revenue 1.3x 4.9x 4.6x
EV/FCF -27.3x 28.4x 27.6x
EV/Operating cash flow -27.3x 23.9x 21.8x
PEG (3Y EPS CAGR) 0.37 2.81 19.31

Growth

14 metrics
MetricADMTSYKABT
Revenue growth (1Y) -2.2% 7.9% 8.1%
Revenue CAGR (3Y) -2.7% 9.8% 5.0%
Gross profit growth (1Y) -6.4% 10.1% 9.2%
Gross profit CAGR (3Y) -7.4% 10.9% 5.9%
Operating income growth (1Y) -93.9% 48.2% -2.2%
Operating income CAGR (3Y) -58.3% 16.4% 6.2%
Net income growth (1Y) -485.4% 23.1% -61.2%
Net income CAGR (3Y) -27.7% 11.9% 1.7%
EPS growth (1Y) -485.4% 23.3% -61.0%
EPS CAGR (3Y) -27.7% 11.7% 1.8%
Operating cash flow growth (1Y) -389.0% 12.7% 9.6%
Operating cash flow CAGR (3Y) -84.7% 19.6% 9.9%
Free cash flow growth (1Y) -389.0% 12.3% 15.5%
Free cash flow CAGR (3Y) -84.7% 21.2% 12.5%

Profitability

14 metrics
MetricADMTSYKABT
Gross margin 39.2% 65.3% 56.6%
EBITDA margin -8.0% 25.2% 23.2%
Operating margin -8.9% 20.7% 15.8%
Pretax margin -12.2% 19.5% 16.1%
Net margin -12.2% 13.8% 11.6%
FCF margin -4.8% 17.4% 16.8%
Operating cash flow margin -4.8% 20.7% 21.3%
Return on equity -67.4% -4.0% 10.4%
Return on assets -20.6% -2.0% 4.9%
Return on invested capital -27.1% 10.0% 6.2%
Return on capital employed -41.9% 13.2% 8.0%
Asset turnover 1.7x 0.6x 0.4x
Cash conversion (OCF / net income) 0.4x 1.5x 1.8x
Stock comp / revenue – 1.0% 1.5%

Financial Health

11 metrics
MetricADMTSYKABT
Debt / assets 22.2% 31.6% 29.9%
Debt / equity 0.7x 0.6x 0.6x
Net debt / EBITDA -0.9x 1.8x 2.5x
Debt / FCF -2.9x 3.3x 4.2x
Liabilities / assets 70.2% 50.4% 52.6%
Equity / assets 29.8% 49.6% 47.4%
Interest coverage -8.0x 9.3x 9.6x
Current ratio 1.0x 2.2x 1.4x
Quick ratio 0.7x 1.1x 0.8x
Cash ratio 0.2x 0.5x 0.3x
Altman Z-score -20.05 4.74 3.34

Shareholder Returns

7 metrics
MetricADMTSYKABT
Dividend yield – 1.1% 2.3%
Net buyback yield – – 0.9%
Shareholder yield – 1.1% 3.2%
Payout ratio (earnings) – – 78.5%
Payout ratio (FCF) – – 54.5%
Dividend growth (1Y) – – 7.2%
Dividend CAGR (3Y) – – 7.5%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusADMTSYKABT
Forward P/E – 19.5xFY2026 19.2xFY2026
EPS, next fiscal year – $15.91FY2026 $5.69FY2026
EPS growth, next FY – +16.7%FY2026 +10.5%FY2026
EPS growth, the year after – +2.5% +10.4%
Revenue, next fiscal year – $26.14BFY2026 $53.00BFY2026
Revenue growth, next FY – +4.1%FY2026 +19.5%FY2026
Revenue growth, the year after – +18.2% -2.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersADMTSYKABT
Held by institutions – 80.3% 79.2%
Institutions holding – 2,267 2,983
Change in shares held, QoQ – +3.2% +0.3%
Institutions buying – 1,105 1,261
Institutions selling – 852 1,379
Buyers to sellers – 1.30 0.91

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ADMTSYKABT
ADMT 1.00 -0.01 -0.06
SYK -0.01 1.00 0.50
ABT -0.06 0.50 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ADMT, SYK and ABT?

Abbott Laboratories (ABT) is the largest by market capitalisation: Adm Tronics Unlimited (ADMT) $4.73M, Stryker (SYK) $130.89B, Abbott Laboratories (ABT) $201.46B.

Which stock is cheaper, ADMT, SYK and ABT?

Stryker (SYK) trades on the lowest price-to-earnings ratio (Adm Tronics Unlimited (ADMT) -12.0x, Stryker (SYK) 36.1x, Abbott Laboratories (ABT) 37.1x). On next year's consensus earnings, Abbott Laboratories (ABT) is cheapest (Stryker (SYK) 19.5x, Abbott Laboratories (ABT) 19.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Abbott Laboratories (ABT) grew revenue fastest over the trailing twelve months: Adm Tronics Unlimited (ADMT) -2.2%, Stryker (SYK) +7.9%, Abbott Laboratories (ABT) +8.1%.

Which company is more profitable?

Stryker (SYK) has the highest net margin (Adm Tronics Unlimited (ADMT) -12.2%, Stryker (SYK) 13.8%, Abbott Laboratories (ABT) 11.6%). On return on invested capital, Stryker (SYK) leads (Adm Tronics Unlimited (ADMT) -27.1%, Stryker (SYK) 10.0%, Abbott Laboratories (ABT) 6.2%).

Which stock has performed better?

Over the past year Abbott Laboratories (ABT) returned the most: Adm Tronics Unlimited (ADMT) -33.3%, Stryker (SYK) -13.3%, Abbott Laboratories (ABT) -11.7%. Over five years, Stryker (SYK) compounded fastest (Adm Tronics Unlimited (ADMT) -11.4%/yr, Stryker (SYK) +2.8%/yr, Abbott Laboratories (ABT) -3.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Adm Tronics Unlimited (ADMT) 0.00%, Stryker (SYK) 0.00%, Abbott Laboratories (ABT) 0.02%. Adm Tronics Unlimited (ADMT) and Stryker (SYK) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Abbott Laboratories (ABT) has been the steadiest (Adm Tronics Unlimited (ADMT) 185.7%, Stryker (SYK) 31.6%, Abbott Laboratories (ABT) 27.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ADMT, SYK and ABT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Abbott Laboratories (ABT) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.